What changed: Platinum-resistant ovarian cancer
Every dated change on the records linked to Platinum-resistant ovarian cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Approval2Regulatory1Trial result4Milestone7This record1
September 2026 · 1
2026 · 1
2025 · 5
- 2025Trial resultKEYNOTE-B96 / ENGOT-ov65KEYNOTE-B96 / ENGOT-ov65 reported
OS 18.
- 2025Trial resultRAINFOL-01 (Rina-S)RAINFOL-01 (Rina-S) reported
ORR 55.
- 2025Trial resultROSELLA / GOG-3073ROSELLA / GOG-3073 reported
OS 16.
- 2025MilestoneKEYNOTE-B96 / ENGOT-ov65KEYNOTE-B96: pembrolizumab with paclitaxel extends survival in PD-L1-positive disease
A milestone in how this cancer is treated.
- 2025MilestoneROSELLA / GOG-3073ROSELLA: relacorilant with nab-paclitaxel extends survival, 16.0 versus 11.9 months
A milestone in how this cancer is treated.
2023 · 2
November 2022 · 1
2022 · 2
2014 · 2
- 2014ApprovalBevacizumabBevacizumab approved in US
Platinum-resistant ovarian cancer with chemotherapy; recurrent/metastatic cervical cancer with chemotherapy
- 2014MilestoneBevacizumabAURELIA: bevacizumab with chemotherapy improves progression-free survival in platinum-resistant disease
A milestone in how this cancer is treated.